Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01651806 · ClinicalTrials.gov registry record · Phase 2
Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty
A Phase 2 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01651806: Completed Phase 2 study, sponsored by Rush University Medical Center.
NCT01651806 is a Phase 2 study that has completed, run by Rush University Medical Center. The registered enrollment target is 65 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01651806, a Phase 2 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
Hypotheses: Primary - A weighted dose of 20 mg/kg of tranexamic acid will be more efficacious than a single uniform dose of 1 gram in primary total knee arthroplasty (TKA) cases. This includes having a greater impact on decreasing blood loss without increasing the occurrence of adverse thromboembolic events in patients undergoing primary, elective total knee arthroplasty. Secondary - TA will decrease blood loss more effectively in women than in men undergoing this procedure.
Primary Outcome
Record intra-operative blood loss through drain output
Interventions
- DRUG Tranexamic Acid standard dose
- DRUG Females Tranexamic Acid weighted dose
- DRUG Females receiving a uniform dose of TA
- DRUG Males Weighted Dose TA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT01651806 record still lists
NCT01651806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 4 interventions - of which Tranexamic Acid standard dose is the first listed.
NCT01651806 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01651806 about?
NCT01651806 is a clinical study titled "Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty". Hypotheses: Primary - A weighted dose of 20 mg/kg of tranexamic acid will be more efficacious than a single uniform dose of 1 gram in primary total knee arthroplasty (TKA) cases. This includes having a greater impact on decreasing blood loss without increasing the occurrence of adverse thromboemboli...
What is the current status of trial NCT01651806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2012-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01651806?
The interventions under investigation include: Tranexamic Acid standard dose (DRUG), Females Tranexamic Acid weighted dose (DRUG), Females receiving a uniform dose of TA (DRUG), Males Weighted Dose TA (DRUG).
Who is sponsoring clinical trial NCT01651806?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01651806's enrollment target sits among peer trials
65 987th of 2000 higher than 1,005 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia